AVEO Oncology Presents Three Posters for
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two...
United States Michael Bailey University Of Florida Health Cancer Center Pharma United Kingdom Drug Administration European Union
Source: globenewswire.com